COMMUNIQUÉS West-GlobeNewswire

Mobile-health Network Solutions Opens New Retail Pharmacy
30/04/2024
SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced the grand opening of ManaPharma [...]
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
30/04/2024
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five (5)-year agreement includes BioRestorative supplying [...]
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
30/04/2024
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
30/04/2024
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDA TM and the discovery of novel monoclonal antibodies Company now expects to end 2024 with [...]
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
30/04/2024
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two [...]
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
30/04/2024
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representing 50 [...]
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
30/04/2024
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, [...]
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
30/04/2024
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will [...]
Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
30/04/2024
BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today [...]
CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial
30/04/2024
ZÜRICH, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the advancement of the Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the [...]
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30/04/2024
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement [...]
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30/04/2024
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira ® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement [...]
EAACI Congress 2024: Innovation and Advances in Allergy Treatment
30/04/2024
Over 150 scientific sessions will be presented during the congress, focusing on advancements in environmental science, food allergies, innovations in immunotherapy, and pediatric allergies, among others. Precision [...]
Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies
30/04/2024
Lors de ce congrès, plus de 150 sessions scientifiques seront présentées. Les sujets abordés se concentreront sur les progrès de la science environnementale, les allergies alimentaires, les innovations en matière d' [...]
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
30/04/2024
Oslo, Norway, 30 April 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST. A physical Annual General Meeting will [...]
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
30/04/2024
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors Co-Founder of Spark Therapeutics with over 20 years of industry experience to support ViaNautis Bio in its next stage of development [...]
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
30/04/2024
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on [...]
BioSenic S.A. : Information on the total number of voting rights and shares
30/04/2024
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
30/04/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 30 avril 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto [...]

Pages